Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1455

Sort by

Sort Order Select

Journal Articles

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Nadine Vollack-Hesse, Olga Oleshko, Sonja Werwitzke, Barbara Solecka-Witulska, Christoph Kannicht, Andreas Tiede

Blood (2021) 137 (8): 1072–1081.

https://doi.org/10.1182/blood.2020006468

Published: 2021

Includes: Supplemental data

Journal Articles

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Blood (2020) 135 (17): 1484–1496.

https://doi.org/10.1182/blood.2019001292

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Pharmacokinetics of Extended Half-Life Factor VIII Products By myPKFiT R Is Useful for Personalized Treatment in Children with Severe Hemophilia a

Risa Matsumura, Keita Tomioka, MD, Shiho Nishimura, MD, Yoko Mizoguchi, MD PhD, Hiroshi Kawaguchi, MD PhD, Masao Kobayashi, MD PhD

Blood (2019) 134 (Supplement_1): 1127.

https://doi.org/10.1182/blood-2019-128149

Published: 2019

Journal Articles

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Jonathan M. Ducore, MD MPH, Shadan Lalezari, PhD, Elena Santagostino, MD PhD, Sanjay P Ahuja, MD, Monika Maas Enriquez, Claudia Tueckmantel, PhD, Mark Reding

Blood (2019) 134 (Supplement_1): 1129.

https://doi.org/10.1182/blood-2019-123947

Published: 2019

Journal Articles

Inter-Laboratory Evaluation of the Recovery of Bay 94-9027 [Jivi®] with One-Stage Clotting and Chromogenic Assays

Piet Meijer, PhD, Richard A. Marlar, PhD, John M. Teare, PhD, Dorothy Adcock, MD

Blood (2019) 134 (Supplement_1): 1124.

https://doi.org/10.1182/blood-2019-125491

Published: 2019

Journal Articles

Bleeding in Mild Hemophilia A Due to a Splice-Site F8 Mutation May be Fully Abrogated By Prothrombotic Gene Variants

Peter H. Cygan, MD, Sarah E. Arnold-Croop, MS, Elizabeth A. Weidman, BS, Fang Chen, PhD, Dajiang J. Liu, PhD, M. Elaine Eyster, MD, Laura Carrel, PhD

Blood (2019) 134 (Supplement_1): 1125.

https://doi.org/10.1182/blood-2019-126026

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Hudan Liu, PhD, Jue Jiang, PhD, Jingchao Wang, PhD, Ming Yue, PhD, Hui Feng, MD PhD, Guoliang Qing, PhD

Blood (2019) 134 (Supplement_1): 732.

https://doi.org/10.1182/blood-2019-130112

Published: 2019

Journal Articles

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Norbert Grząśko, MD PhD, Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Jan Dürig, Sara Bringhen, Mattia D'Agostino, MD, Barbara Gamberi, Elena Rivolti, MD, Angelo Vacca, MD PhD, Roberto Ria, MD, Artur Jurczyszyn, MD, Jorge Castellano Acosta, MD, Doris Lang, Guy Lemaillet, PhD, Bansod Sudhir, MD, Monika Szarejko, MD

Blood (2019) 134 (Supplement_1): 1899.

https://doi.org/10.1182/blood-2019-129827

Published: 2019

Journal Articles

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Ben Buelow, MD PhD, Anita D'Souza, MBBS, Cesar Rodriguez, MD, Ravi Vij, MBBS, Rajneesh Nath, MD, Melinda Snyder, MS, Duy Pham, MBA, Ashwin Patel, PhD, Suhasini Iyer, PhD

Blood (2019) 134 (Supplement_1): 1874.

https://doi.org/10.1182/blood-2019-123220

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Fang Liu, MD PhD, Hongyu Zhang, MD PhD, Xiao Wang, MD PhD, Yisong Xiong, PhD, Yuanzhen Cao, Yi Su, MD, Hai Yi, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 38.

https://doi.org/10.1182/blood-2019-122964

Published: 2019

Journal Articles

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Namita Joshi, PhD MS, BPharm, Xinyi Ng, Marc Botteman, MS, MA, Nanxin Li, Rachel Shah, BS, Nisha Jain, Nicole Lyn, Jun Su

Blood (2019) 134 (Supplement_1): 2122.

https://doi.org/10.1182/blood-2019-126774

Published: 2019

Journal Articles

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Shawn X. Sun, Yanyu Wu, Michael McDermott, Marjolijn van Keep

Blood (2019) 134 (Supplement_1): 2102.

https://doi.org/10.1182/blood-2019-124421

Published: 2019

Journal Articles

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Ang Li, MD, Catlin Goodfriend, PharmD, John Sokol, PharmD, Rebecca Kruse-Jarres, MDMPH

Blood (2019) 134 (Supplement_1): 2178.

https://doi.org/10.1182/blood-2019-128083

Published: 2019

Journal Articles

Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes

Declan Noone, MSc, Gabriel Pedra, PhD, Sohaib Asghar, MSc, Jamie O'Hara, MSc, Eileen K Sawyer, PhD, Nanxin (Nick) Li, PhD

Blood (2019) 134 (Supplement_1): 2118.

https://doi.org/10.1182/blood-2019-126576

Published: 2019

Journal Articles

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Alfonso Iorio, Monika Maas Enriquez, Heinz Delesen, Alexander Solms, Stacy E. Croteau, Erik Berntorp

Blood (2019) 134 (Supplement_1): 3637.

https://doi.org/10.1182/blood-2019-127046

Published: 2019

Journal Articles

A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim (Dulastin®) after Single Administration in Pediatric Patients

Kyung Taek Hong, MD, Soyoung Lee, Jaeseong Oh, Jung Yoon Choi, MD, Hee Young Shin, MD PhD, Kyung-Sang Yu, MD PhD, Hyoung Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3594.

https://doi.org/10.1182/blood-2019-125266

Published: 2019

Journal Articles

A Novel Platelet-Targeting Fibrinolytic Strategy: Endocytosed Urokinase By Megakaryocytes Is Stored in α-Granules and Is Functional In Vivo in a Murine Model of Thrombosis

Hyunsook Ahn, MSc, John Tkaczynski, BS, Khalil Bdeir, PhD, Victoria Stepanova, Douglas B. Cines, MD, Mortimer Poncz, MD, Sergei Zaitsev

Blood (2019) 134 (Supplement_1): 3627.

https://doi.org/10.1182/blood-2019-124501

Published: 2019

NARROW

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Pharmacokinetics of Extended Half-Life Factor VIII Products By myPKFiT R Is Useful for Personalized Treatment in Children with Severe Hemophilia a

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Inter-Laboratory Evaluation of the Recovery of Bay 94-9027 [Jivi®] with One-Stage Clotting and Chromogenic Assays

Bleeding in Mild Hemophilia A Due to a Splice-Site F8 Mutation May be Fully Abrogated By Prothrombotic Gene Variants

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim (Dulastin®) after Single Administration in Pediatric Patients

A Novel Platelet-Targeting Fibrinolytic Strategy: Endocytosed Urokinase By Megakaryocytes Is Stored in α-Granules and Is Functional In Vivo in a Murine Model of Thrombosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only